{"schema_version":"secwatch.filing_event.v1","accession":"0001654954-22-015036","form_type":"8-K","ticker":"DRMA","cik":"0001853816","company_name":"Dermata Therapeutics, Inc.","filed_at":"2022-11-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.767369+00:00","generated_at":"2026-06-21T23:55:47.512107+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Dermata Therapeutics Q3 2022: cash $8.1M; DMT310 rosacea Phase 2 top-line due Dec 2022","bullets":["Cash and equivalents $8.1M as of Sep 30, 2022, down from $10.8M at Dec 31, 2021; runway into Q3 2023.","R&D expenses $1.6M (Q3 2022) vs $0.8M (Q3 2021) due to increased DMT310 program costs.","G&A expenses flat at $0.9M; stock-based comp $0.2M for G&A and $0.05M for R&D in Q3 2022.","DMT310 Phase 2 topline results in moderate-to-severe rosacea expected December 2022.","DMT310 Phase 3 program for moderate-to-severe acne anticipated to start 1H 2023 after FDA meeting."],"urls":{"canonical":"https://secwatch.observer/filing/0001654954-22-015036","json":"https://secwatch.observer/filing/0001654954-22-015036.json","markdown":"https://secwatch.observer/filing/0001654954-22-015036.md","text":"https://secwatch.observer/filing/0001654954-22-015036.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1853816/000165495422015036/0001654954-22-015036-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1853816/000165495422015036/drma_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T23:55:47.512107+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"81747000b59385a8fa2ef83751840797348a2662","claim":"Dermata Therapeutics, Inc. reported financial results for quarter ended September 30, 2022.","evidence_excerpt":"Dermata Therapeutics, Inc. (the “Company”) issued a press release disclosing certain information regarding its results of operations for the fiscal period ended September 30, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1853816/000165495422015036/0001654954-22-015036-index.htm","confidence":0.4,"family_label":"Earnings Releases","details":[{"label":"Period","value":"quarter ended September 30, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}